U.S., Oct. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07884188) titled 'Becotatug Vedotin Plus Pucotenlimab for Metastatic Colorectal Cancer' on Oct. 13.
Brief Summary: The BECOME trial will study whether becotatug vedotin combined with pucotenlimab can shrink tumors and how safe this treatment is in adults with colorectal cancer that has returned or spread after at least two prior lines of standard treatment. The study described in the informed consent form is for patients whose tumors test positive for a protein called epidermal growth factor receptor (EGFR).
Becotatug vedotin, also known as MRG003, is an antibody-drug conjugate (ADC). It combines an antibody that recognizes EGFR with a drug designed...